Literature DB >> 32620470

EML4-ALK Fusion as a Resistance Mechanism to Osimertinib and Its Successful Management With Osimertinib and Alectinib: Case Report and Review of the Literature.

Ullas Batra1, Mansi Sharma2, B P Amrith2, Anurag Mehta3, Parveen Jain2.   

Abstract

Entities:  

Keywords:  Combination therapy; EGFR mutation; NSCLC; Personalized medicine; Resistance pathways

Mesh：

Substances：

Year:  2020        PMID： 32620470     DOI： 10.1016/j.cllc.2020.05.016

Source DB:  PubMed          Journal:  Clin Lung Cancer        ISSN： 1525-7304            Impact factor:   4.785


× No keyword cloud information.
  3 in total

1.  Successful management of a lung cancer patient harbouring both EGFR mutation and EML4-ALK fusion gene with disseminated intravascular coagulation.

Authors:  Kohei Fujita; Megumi Naka; Takanori Ito; Osamu Kanai; Koichi Maekawa; Koichi Nakatani; Tadashi Mio
Journal:  Respir Med Case Rep       Date:  2021-03-19

Review 2.  Mechanisms and management of 3rd‑generation EGFR‑TKI resistance in advanced non‑small cell lung cancer (Review).

Authors:  Jingyi He; Zhengrong Huang; Linzhi Han; Yan Gong; Conghua Xie
Journal:  Int J Oncol       Date:  2021-09-24       Impact factor: 5.650

Review 3.  Alternative Treatment Options to ALK Inhibitor Monotherapy for EML4-ALK-Driven Lung Cancer.

Authors:  Savvas Papageorgiou; Sarah L Pashley; Laura O'Regan; Sam Khan; Richard Bayliss; Andrew M Fry
Journal:  Cancers (Basel)       Date:  2022-07-15       Impact factor: 6.575
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.